{
    "clinical_study": {
        "@rank": "68651", 
        "arm_group": [
            {
                "arm_group_label": "Mild anemia, normal hematinics", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo"
            }, 
            {
                "arm_group_label": "Anemia, normal hematinics", 
                "arm_group_type": "Experimental", 
                "description": "Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given"
            }, 
            {
                "arm_group_label": "Deficeicnt hematinics", 
                "arm_group_type": "Other", 
                "description": "Iron supplement will be provided"
            }
        ], 
        "brief_summary": {
            "textblock": "To establish the efficacy of screening for anemia and treatment of mild anemia with iron and\n      vitamins prior to THR and TKR as a means of increasing hemoglobin and reducing perioperative\n      allogeneic blood transfusion."
        }, 
        "brief_title": "Iron and Vitamin Adminstration Prior to Joint Replacement to Prevent Transfusion", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Excessive Amount of Blood / Fluid Transfusion", 
        "detailed_description": {
            "textblock": "Patients with mild anemia will be identified at preoperative clinic visit\n\n        -  Patients will be screened for inclusion and exclusion criteria\n\n        -  Eligible patients will have laboratory testing performed as follows: CBC, liver and\n           kidney function tests, serum iron, transferrin, ferritin, serum folic acid, vitamin B12\n           and C-reactive protein\n\n        -  Patients will be assigned to a deficient group or non-deficient group depending upon\n           laboratory hematinic values\n\n        -  Patients in the \"non-deficient' group will be randomized using a computer-generated\n           code to treatment or no treatment\n\n        -  Treatment will begin within 2 weeks of laboratory testing and 4-6 weeks prior to\n           surgery.\n\n        -  Hematinic therapy will consist of oral ferric hydrochloride polymaltose 200 mg/d and\n           folic acid 0.4 mg/d; sublingual vitamin B12 1000 \u00b5g three times a week\n\n        -  On the day of surgery laboratory testing will be performed as follows: CBC, kidney and\n           liver function tests, serum iron, transferrin, ferritin, serum folic acid, vitamin B12\n           and C-reactive protein.\n\n        -  The same surgical team in each center will operate on all study patients and will be\n           blinded to the preoperative hemoglobin\n\n        -  Routine postoperative management will be provided as determined by the treating\n           physicians\n\n        -  Blood transfusion will be decided upon by a study physician at each center blinded to\n           the patients' group assignment and preoperative hemoglobin\n\n        -  The primary outcome will be perioperative blood transfusion (from 24 hours prior to\n           surgery until hospital discharge)\n\n        -  Secondary outcomes will be length of hospitalization, postoperative wound infection,\n           walking ability across room at 30 days"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 50 years\n\n          -  Ability to provide informed consent\n\n          -  Elective THR or TKR\n\n          -  Mild anemia: Hematocrit 29-39% in men, 29-36% in women\n\n        Exclusion Criteria:\n\n          -  Identified cause of anemia excluding hematinic deficiency\n\n          -  Known source of blood loss\n\n          -  Known coagulopathy\n\n          -  Unstable coronary syndrome in the previous 3 months\n\n          -  Pathologic fracture, presence of malignancy\n\n          -  Repeat THR or TKR\n\n          -  Orthopedic trauma within the previous 3 months\n\n          -  ASA class \u2265 4\n\n          -  Creatinine clearance < 30 ml/min\n\n          -  AST/ALT > 2x upper limit of normal\n\n          -  Preexisting use of hematinic agents\n\n          -  Planned acute normovolemic hemodilution\n\n          -  Refusal to receive blood products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676740", 
            "org_study_id": "MMCHI0112"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Anemia, normal hematinics", 
                    "Deficeicnt hematinics"
                ], 
                "description": "Pills to be swallowed", 
                "intervention_name": "Iron Supplement,", 
                "intervention_type": "Drug", 
                "other_name": "Ferrifol"
            }, 
            {
                "arm_group_label": "Mild anemia, normal hematinics", 
                "description": "Daily administration of active drug or placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hematinics", 
                "Vitamins", 
                "Iron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hematinic therapy", 
            "blood transfusion", 
            "joint replacement"
        ], 
        "lastchanged_date": "August 31, 2012", 
        "location": {
            "contact": {
                "email": "martinel@clalit.org.il", 
                "last_name": "Martin H Ellis, MD", 
                "phone": "972-9-7471822"
            }, 
            "facility": {
                "address": {
                    "city": "Kfar Saba", 
                    "country": "Israel", 
                    "zip": "44281"
                }, 
                "name": "Meir Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized Ttrial to Establish the Efficacy of Hematinic Agents in Patietns With Mild Anemia Undergoing Total Hip or Knee Replacement in Avoiding Blood Transfusion", 
        "overall_official": {
            "affiliation": "Meir Medical Center", 
            "last_name": "Martin H Ellis, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Clalit Health Services", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Perioperative blood transfusion", 
            "safety_issue": "No", 
            "time_frame": "1 day prior to surgery until hospital discharge"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676740"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Meir Medical Center", 
            "investigator_full_name": "Martin Ellis", 
            "investigator_title": "Head Hematology Institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meir Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}